Chromosome 9p and 10q losses predict unfavorable outcome in low-grade gliomas

Neuro-Oncology

Volumn 12, Issue 1, 2010, Pages 2-6

  Houillier, Caroline ^a   Mokhtari, Karima ^a,b   Carpentier, Catherine ^b   Crinière, Emmanuelle ^b   Marie, Yannick ^b   Rousseau, Audrey ^a,b   Kaloshi, Gentian ^a   Dehais, Caroline ^a   Laffaire, Julien ^b   Laigle Donadey, Florence ^a,b   Hoang Xuan, Khê ^a,b   Sanson, Marc ^a,b   Delattre, Jean Yves ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Chromosomes 9p and 10q; Low grade gliomas; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHROMOSOME 10Q; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME 9P; DISEASE ASSOCIATION; DNA DETERMINATION; FEMALE; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 9; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; KAPLAN-MEIERS ESTIMATE; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

EID: 75749095977     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop002     Document Type: Article

References (22)

1. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma. European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996;36:549-556.
2. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20:2076-2084.
3. Shaw E, Arusell R, Scheuthauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/ Eastern Cooperative Oncology Group study. J Clin Oncol. 2002;20:2267-2276.
4. Claus EB, Black PM. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973-2001. Cancer. 2006;106:1358-1363.
5. Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for lowgrade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology. 2007;68:1831-1836.
6. Kujas M, Lejeune J, Benouaich-Amiel A, et al. Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. Ann Neurol. 2005;58:322-326.
7. von Deimling A, Louis DN, Wiestler OD. Molecular pathways in the formation of gliomas. Glia. 1995;15:328-338.
8. Dehais C, Laigle-Donadey F, Marie Y, et al. Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer. 2006;107:1891-1897.
9. Houillier C, Lejeune J, Benouaich-Amiel A, et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer. 2006;106:2218-2223.
10. He J, Mokhtari K, Sanson M, et al. Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol. 2001;60:863-871.
11. McCormack BM, Miller DC, Budzilovich GN, et al. Treatment and survival of low-grade astrocytoma in adults - 1977-1988. Neurosurgery. 1992;31:636-642.
12. Hulsebos TJ, Oskam NT, Troost D, et al. Dynamics of genetic alterations associated with glioma recurrence. Genes Chromosomes Cancer. 1998;23:153-158.
13. Idbaih A, Carvalho Silva R, Crinière E, et al. Genomic changes in progression of low-grade gliomas. J Neurooncol. 2008;90:133-140.
14. Weber RG, Sabel M, Reifenberger J, et al. Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization. Oncogene. 1996;13:983-994.
15. Hulsebos TJ, Troost D, Leenstra S. Molecular-genetic characterisation of gliomas that recur as same grade or higher grade tumours. J Neurol Neurosurg Psychiatry. 2004;75:723-726.
16. Kitange G, Misra A, Law M, et al. Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. Genes Chromosomes Cancer. 2005;42:68-77.
17. Trost D, Ehrler M, Fimmers R, et al. Identification of genomic aberrations associated with shorter overall survival in patients with oligodendroglial tumors. Int J Cancer. 2007;120:2368-2376.
18. Thiessen B, Maguire JA, McNeil K, et al. Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. J Neurooncol. 2003;64:271-278.
19. Coons SW, Johnson PC, Scheithauer BW, et al. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer. 1997;79:1381-1393.
20. Mariani L, Deiana G, Vassella E, et al. Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. J Clin Oncol. 2006;24:4758-4763.
21. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66:9852-9861.
22. Iwamoto FM, Nicolardi L, Demopoulos A, et al. Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. J Neurooncol. 2008;88:293-298.